Trial Patient Dies After Receiving CRISPR Gene Therapy

(MedPage Today) -- A patient with transthyretin amyloidosis (ATTR) who received the investigational gene therapy nexiguran ziclumeran (nex-z) in a phase III trial died, Intellia Therapeutics said.
The news came days after the company paused the...